• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A potential central nervous system niche for trastuzumab deruxtecan in patients with HER2-expressing non-small cell lung cancer.

作者信息

Lazaratos Anna-Maria, Bian David J H, Petrecca Kevin, Guiot Marie-Christine, Dankner Matthew

机构信息

Department of Medicine, Université de Montreal, Montreal, QC, Canada.

Rosalind and Morris Goodman Cancer Institute, McGill University, Montreal, QC, Canada.

出版信息

Transl Lung Cancer Res. 2024 Dec 31;13(12):3824-3830. doi: 10.21037/tlcr-24-856. Epub 2024 Dec 27.

DOI:10.21037/tlcr-24-856
PMID:39830768
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11736602/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/680c/11736602/6713d1707396/tlcr-13-12-3824-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/680c/11736602/6713d1707396/tlcr-13-12-3824-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/680c/11736602/6713d1707396/tlcr-13-12-3824-f1.jpg

相似文献

1
A potential central nervous system niche for trastuzumab deruxtecan in patients with HER2-expressing non-small cell lung cancer.曲妥珠单抗德鲁替康在HER2表达的非小细胞肺癌患者中的潜在中枢神经系统微环境。
Transl Lung Cancer Res. 2024 Dec 31;13(12):3824-3830. doi: 10.21037/tlcr-24-856. Epub 2024 Dec 27.
2
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial.曲妥珠单抗-德鲁替康用于转移性非小细胞肺癌患者（DESTINY-Lung01）：一项单臂、2 期临床试验中 HER2 过表达队列的主要结果。
Lancet Oncol. 2024 Apr;25(4):439-454. doi: 10.1016/S1470-2045(24)00064-0.
3
Analytical and Clinical Validation of the Oncomine Dx Target Test to Assess HER2 Mutation Status in Tumor Tissue Samples From Patients With Non-Small Cell Lung Cancer Treated With Trastuzumab Deruxtecan in the DESTINY-Lung01 and DESTINY-Lung02 Studies.在DESTINY-Lung01和DESTINY-Lung02研究中，对用于评估接受曲妥珠单抗德鲁昔单抗治疗的非小细胞肺癌患者肿瘤组织样本中HER2突变状态的Oncomine Dx靶向检测进行分析和临床验证。
Arch Pathol Lab Med. 2025 Jun 1;149(6):542-549. doi: 10.5858/arpa.2024-0014-OA.
4
Metastatic -amplified non-small-cell lung cancer treated with trastuzumab deruxtecan.接受曲妥珠单抗德鲁昔单抗治疗的转移性扩增非小细胞肺癌。
BMJ Case Rep. 2023 May 8;16(5):e253260. doi: 10.1136/bcr-2022-253260.
5
Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer: a plain language summary of the DESTINY-Lung01 study.曲妥珠单抗 deruxtecan 治疗 HER2 突变型非小细胞肺癌：DESTINY-Lung01 研究的通俗易懂总结。
Future Oncol. 2024;20(27):1961-1971. doi: 10.1080/14796694.2024.2355724. Epub 2024 Jul 16.
6
The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre.在单中心接受曲妥珠单抗德卢替康治疗的HER2阳性和HER2低表达的经大量预处理的转移性乳腺癌患者的真实世界临床结局
Curr Oncol. 2024 Dec 24;32(1):1. doi: 10.3390/curroncol32010001.
7
Analytical and Clinical Validation of the Plasma-Based Guardant360 CDx Test for Assessing HER2 (ERBB2) Mutation Status in Patients with Non-Small-Cell Lung Cancer for Treatment with Trastuzumab Deruxtecan in DESTINY-Lung01/02.基于血浆的Guardant360 CDx检测在DESTINY-Lung01/02研究中评估非小细胞肺癌患者HER2（ERBB2）突变状态以指导曲妥珠单抗德鲁昔单抗治疗的分析和临床验证
J Mol Diagn. 2025 Feb;27(2):119-129. doi: 10.1016/j.jmoldx.2024.11.006.
8
Trastuzumab Deruxtecan in -Mutant Non-Small-Cell Lung Cancer.曲妥珠单抗 deruxtecan 治疗 - 突变型非小细胞肺癌。
N Engl J Med. 2022 Jan 20;386(3):241-251. doi: 10.1056/NEJMoa2112431. Epub 2021 Sep 18.
9
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.曲妥珠单抗-德鲁替康（DS-8201）治疗人表皮生长因子受体 2（HER2）表达的转移性结直肠癌（DESTINY-CRC01）患者：一项多中心、开放标签、Ⅱ期临床试验。
Lancet Oncol. 2021 Jun;22(6):779-789. doi: 10.1016/S1470-2045(21)00086-3. Epub 2021 May 4.
10
HER2-Altered Non-Small Cell Lung Cancer: A Journey from Current Approaches to Emerging Strategies.HER2改变的非小细胞肺癌：从当前方法到新兴策略的历程
Cancers (Basel). 2024 May 26;16(11):2018. doi: 10.3390/cancers16112018.

本文引用的文献

1
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial.曲妥珠单抗德鲁昔单抗用于伴或不伴脑转移的HER2阳性晚期乳腺癌：一项3b/4期试验
Nat Med. 2024 Dec;30(12):3717-3727. doi: 10.1038/s41591-024-03261-7. Epub 2024 Sep 13.
2
A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases.曲妥珠单抗德鲁替康用于伴脑转移的人表皮生长因子受体2（HER2）阳性转移性乳腺癌患者的汇总分析。
Ann Oncol. 2024 Dec;35(12):1169-1180. doi: 10.1016/j.annonc.2024.08.2347. Epub 2024 Sep 5.
3
Analysis of HER2 expression changes from breast primary to brain metastases and the impact of HER2-low expression on overall survival.
分析HER2从乳腺原发灶到脑转移灶的表达变化以及HER2低表达对总生存期的影响。
Neuro Oncol. 2025 Jan 12;27(1):184-194. doi: 10.1093/neuonc/noae163.
4
FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations.FDA 批准摘要：fam-trastuzumab deruxtecan-nxki 用于不可切除或转移性非小细胞肺癌伴激活的 HER2 突变。
Oncologist. 2024 Aug 5;29(8):667-671. doi: 10.1093/oncolo/oyae151.
5
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial.曲妥珠单抗-德鲁替康用于转移性非小细胞肺癌患者（DESTINY-Lung01）：一项单臂、2 期临床试验中 HER2 过表达队列的主要结果。
Lancet Oncol. 2024 Apr;25(4):439-454. doi: 10.1016/S1470-2045(24)00064-0.
6
Efficacy of immunotherapy in HER2-mutated non-small cell lung cancer: a single-arm meta-analysis.免疫疗法在HER2突变型非小细胞肺癌中的疗效：一项单臂荟萃分析。
J Cancer Res Clin Oncol. 2024 Jan 27;150(2):42. doi: 10.1007/s00432-023-05509-0.
7
Opportunities and Challenges for a Histology-Agnostic Utilization of Trastuzumab Deruxtecan.曲妥珠单抗-德鲁替康在组织学上的应用的机遇与挑战
Curr Oncol Rep. 2023 Dec;25(12):1467-1482. doi: 10.1007/s11912-023-01469-3. Epub 2023 Nov 8.
8
Management of HER2 alterations in non-small cell lung cancer - The past, present, and future.非小细胞肺癌中HER2改变的管理——过去、现在与未来
Lung Cancer. 2023 Dec;186:107385. doi: 10.1016/j.lungcan.2023.107385. Epub 2023 Sep 28.
9
Trastuzumab Deruxtecan in Patients With -Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial.曲妥珠单抗-德曲妥珠单抗用于 - 突变型转移性非小细胞肺癌患者：来自随机、II 期 DESTINY-Lung02 试验的主要结果。
J Clin Oncol. 2023 Nov 1;41(31):4852-4863. doi: 10.1200/JCO.23.01361. Epub 2023 Sep 11.
10
Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: a systematic review and single-arm meta-analysis.曲妥珠单抗 deruxtecan 治疗乳腺癌患者的间质性肺病和心脏毒性发生率：系统评价和单臂荟萃分析。
ESMO Open. 2023 Aug;8(4):101613. doi: 10.1016/j.esmoop.2023.101613. Epub 2023 Jul 23.